Designer Glycopeptides for Cytotoxic T Cell-based Elimination of Carcinomas

Yanfei Xu, Sandra J Gendler, Alessandra Franco

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Tumors express embryonic carbohydrate antigens called tumor-associated carbohydrate antigens (TACA). TACA-containing glycopeptides are appealing cytotoxic T cell (CTL)-based vaccines to prevent or treat cancer because the same sugar moieties are expressed in a variety of tumors, rendering a vaccination strategy applicable in a large population. Here we demonstrate that by using glycopeptides with high affinity for the major histocompatibility complex and glycosylated in a position corresponding to a critical T cell receptor (TcR) contact, it is possible to induce anti-TACA CTL in vivo. In the current study we show that designer glycopeptides containing the Thomsen-Freidenreich (TF) antigen (β-Gal-[1→3]-α -GalNAc-O-serine) are immunogenic in vivo and generate TF-specific CTL capable of recognizing a variety of tumor cells in vitro including a MUC1-expressing tumor. The fine specificity of the TF-specific CTL repertoire indicates that the TcR recognize the glycosylated amino acid residue together with TF in a conventional major histocompatibility complex class I-restricted fashion. These results have high potential for immunotherapy against a broad range of tumors.

Original languageEnglish (US)
Pages (from-to)707-716
Number of pages10
JournalJournal of Experimental Medicine
Volume199
Issue number5
DOIs
StatePublished - Mar 1 2004

Fingerprint

Glycopeptides
Tumor-Associated Carbohydrate Antigens
Carcinoma
T-Lymphocytes
Neoplasms
T-Cell Antigen Receptor
Major Histocompatibility Complex
Antigens
Immunotherapy
Serine
Vaccination
Vaccines
Carbohydrates
Amino Acids
Population

Keywords

  • Carcinomas
  • CTL
  • Glycopeptides
  • Immunotherapy
  • Tumor-associated carbohydrate antigens

ASJC Scopus subject areas

  • Immunology

Cite this

Designer Glycopeptides for Cytotoxic T Cell-based Elimination of Carcinomas. / Xu, Yanfei; Gendler, Sandra J; Franco, Alessandra.

In: Journal of Experimental Medicine, Vol. 199, No. 5, 01.03.2004, p. 707-716.

Research output: Contribution to journalArticle

@article{b906583aa96a48e3a95a86123a25da75,
title = "Designer Glycopeptides for Cytotoxic T Cell-based Elimination of Carcinomas",
abstract = "Tumors express embryonic carbohydrate antigens called tumor-associated carbohydrate antigens (TACA). TACA-containing glycopeptides are appealing cytotoxic T cell (CTL)-based vaccines to prevent or treat cancer because the same sugar moieties are expressed in a variety of tumors, rendering a vaccination strategy applicable in a large population. Here we demonstrate that by using glycopeptides with high affinity for the major histocompatibility complex and glycosylated in a position corresponding to a critical T cell receptor (TcR) contact, it is possible to induce anti-TACA CTL in vivo. In the current study we show that designer glycopeptides containing the Thomsen-Freidenreich (TF) antigen (β-Gal-[1→3]-α -GalNAc-O-serine) are immunogenic in vivo and generate TF-specific CTL capable of recognizing a variety of tumor cells in vitro including a MUC1-expressing tumor. The fine specificity of the TF-specific CTL repertoire indicates that the TcR recognize the glycosylated amino acid residue together with TF in a conventional major histocompatibility complex class I-restricted fashion. These results have high potential for immunotherapy against a broad range of tumors.",
keywords = "Carcinomas, CTL, Glycopeptides, Immunotherapy, Tumor-associated carbohydrate antigens",
author = "Yanfei Xu and Gendler, {Sandra J} and Alessandra Franco",
year = "2004",
month = "3",
day = "1",
doi = "10.1084/jem.20031865",
language = "English (US)",
volume = "199",
pages = "707--716",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "5",

}

TY - JOUR

T1 - Designer Glycopeptides for Cytotoxic T Cell-based Elimination of Carcinomas

AU - Xu, Yanfei

AU - Gendler, Sandra J

AU - Franco, Alessandra

PY - 2004/3/1

Y1 - 2004/3/1

N2 - Tumors express embryonic carbohydrate antigens called tumor-associated carbohydrate antigens (TACA). TACA-containing glycopeptides are appealing cytotoxic T cell (CTL)-based vaccines to prevent or treat cancer because the same sugar moieties are expressed in a variety of tumors, rendering a vaccination strategy applicable in a large population. Here we demonstrate that by using glycopeptides with high affinity for the major histocompatibility complex and glycosylated in a position corresponding to a critical T cell receptor (TcR) contact, it is possible to induce anti-TACA CTL in vivo. In the current study we show that designer glycopeptides containing the Thomsen-Freidenreich (TF) antigen (β-Gal-[1→3]-α -GalNAc-O-serine) are immunogenic in vivo and generate TF-specific CTL capable of recognizing a variety of tumor cells in vitro including a MUC1-expressing tumor. The fine specificity of the TF-specific CTL repertoire indicates that the TcR recognize the glycosylated amino acid residue together with TF in a conventional major histocompatibility complex class I-restricted fashion. These results have high potential for immunotherapy against a broad range of tumors.

AB - Tumors express embryonic carbohydrate antigens called tumor-associated carbohydrate antigens (TACA). TACA-containing glycopeptides are appealing cytotoxic T cell (CTL)-based vaccines to prevent or treat cancer because the same sugar moieties are expressed in a variety of tumors, rendering a vaccination strategy applicable in a large population. Here we demonstrate that by using glycopeptides with high affinity for the major histocompatibility complex and glycosylated in a position corresponding to a critical T cell receptor (TcR) contact, it is possible to induce anti-TACA CTL in vivo. In the current study we show that designer glycopeptides containing the Thomsen-Freidenreich (TF) antigen (β-Gal-[1→3]-α -GalNAc-O-serine) are immunogenic in vivo and generate TF-specific CTL capable of recognizing a variety of tumor cells in vitro including a MUC1-expressing tumor. The fine specificity of the TF-specific CTL repertoire indicates that the TcR recognize the glycosylated amino acid residue together with TF in a conventional major histocompatibility complex class I-restricted fashion. These results have high potential for immunotherapy against a broad range of tumors.

KW - Carcinomas

KW - CTL

KW - Glycopeptides

KW - Immunotherapy

KW - Tumor-associated carbohydrate antigens

UR - http://www.scopus.com/inward/record.url?scp=1542283702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542283702&partnerID=8YFLogxK

U2 - 10.1084/jem.20031865

DO - 10.1084/jem.20031865

M3 - Article

VL - 199

SP - 707

EP - 716

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 5

ER -